Clinical outcomes of erythropoietin use in heart failure patients with anemia of chronic kidney disease

Journal of Cardiac Failure

Volumn 20, Issue 5, 2014, Pages 327-333

  Jackevicius, Cynthia A ^a,b,c,d,e   Fan, Cindy Shutieng ^a,b   Warner, Alberta ^b,f  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiac; health policy; outcome research

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEMOGLOBIN; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; NITROGEN; RECOMBINANT ERYTHROPOIETIN; UREA; ERYTHROPOIETIN;

ACUTE CORONARY SYNDROME; AGE; AGED; ANEMIA; ARTICLE; CARDIORENAL ANEMIA SYNDROME; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; DISEASE FREE SURVIVAL; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; COHORT STUDIES; DISEASE-FREE SURVIVAL; ERYTHROPOIETIN; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84899850056     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2014.02.001     Document Type: Article

References (35)

1. C.A. Herzog, H.A. Muster, S. Li, and A. Collins Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population J Card Fail 10 2004 467 472
2. H.F. Groenveld, J.L. Januzzi, K. Damman, J.V. Wijngaarden, H.L. Hillege, and D.J. Veldhuisen et al. Anemia and mortality in heart failure patients: a systematic review and meta-analysis J Am Coll Cardiol 52 2008 818 827
3. P. Ponikowski, S.D. Anker, J. Szachniewicz, D. Okonko, M. Ledwidge, and R. Zymlinski et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 49 2007 753 762
4. A. Kazory, and E.A. Ross Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol 53 2009 639 647
5. A.S. Go, J. Yang, L.M. Ackerson, K. Lepper, S. Robbins, and B.M. Massie et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) study Circulation 113 2006 2713 2723
6. D.S. Silverberg, D. Wexler, A. Iaina, and D. Schwartz Anaemia management in cardio renal disease J Ren Care 36 Suppl 1 2010 86 96
7. I.S. Anand Anemia and chronic heart failure: implications and treatment options J Am Coll Cardiol 52 2008 501 511
8. S. Blecker, M. Paul, G. Taksler, G. Ogedegbe, and S. Katz Heart failure-associated hospitalizations in the united states J Am Coll Cardiol 61 2013 1259 1267
9. J.B. Young, W.T. Abraham, N.M. Albert, S.W. Gattis, M. Gheorghiade, and B.H. Greenberg et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry) Am J Cardiol 101 2008 223 230
10. T.B. Horwich, G.C. Fonarow, M.A. Hamilton, W.R. MacLellan, and J. Borenstein Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure J Am Coll Cardiol 39 2002 1780 1786
11. M.S. Maurer, S. Teruya, B. Chakraborty, S. Helmke, and D. Mancini Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy Circ Heart Fail 6 2013 254 263
12. K. Swedberg, J.B. Young, I.S. Anand, S. Cheng, A.S. Desai, and R. Diaz et al. Treatment of anemia with darbepoetin alfa in systolic heart failure N Engl J Med 368 2013 1210 1219
13. J.C. Luthi, W.D. Flanders, M. Burnier, B. Burnand, and W.M. McClellan Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients BMC Nephrol 7 2006 3 13
14. A. Besarab, W.K. Bolton, J.K. Browne, J.C. Egrie, A.R. Nissenson, and D.M. Okamoto et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
15. D.S. Silverberg, D. Wexler, M. Blum, G. Keren, D. Sheps, and E. Leibovitch et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations J Am Coll Cardiol 35 2000 1737 1744
16. D.S. Silverberg, D. Wexler, D. Sheps, M. Blum, G. Keren, and R. Baruch et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study J Am Coll Cardiol 37 2001 1775 1780
17. A.K. Singh, L. Szczech, K.L. Tang, H. Barnhart, S. Sapp, and M. Wolfson et al. Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098
18. M.A. Pfeffer, E.A. Burdman, C.Y. Chen, M.E. Cooper, D.D. Zeeuw, and K.U. Eckardt et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
19. P.A. McCullough, H.X. Barnhart, J.K. Inrig, D. Reddan, S. Sapp, and U.D. Patel et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease Am J Nephrol 37 2013 549 558
20. US Food and Drug Administration. FDA drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents in chronic kidney disease. June 24, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm. Accessed January 13, 2013.
21. D.C. Cowper, D.M. Hynes, J.D. Kubal, and P.A. Murphy Using administrative databases for outcomes research: select examples from VA health services research and development J Med Syst 23 1999 249 259
22. A.S. Levey, T. Greene, J.W. Kusek, and G.J. Beck A simplified equation to predict glomerular filtration rate from serum creatinine J Am Soc Nephrol 11 2000 155A
23. National Kidney Foundation K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults Am J Kidney Dis 47 5 Suppl 3 2006 S17 S57
24. T.B. Drueke, F. Locatelli, N. Clyne, K.U. Eckardt, I.C. Macdougall, and D. Tsakiris et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084
25. A. Desai, E. Lewis, S. Solomon, J. McMurray, and M. Pfeffer Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis Eur J Heart Fail 12 2010 936 942
26. L. Kleijn, B.D. Westenbrink, and P. Meer Erythropoietin and heart failure: the end of a promise? Eur J Heart Fail 15 2013 479 481
27. N.D. Vaziri, and X.J. Zhou Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease Nephrol Dial Transplant 24 2009 1082 1088
28. S. Shoji, M. Inaba, N. Tomosugi, S. Okuno, M. Ichii, and T. Yamakawa et al. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients Euro J Haem 90 2013 237 244
29. A.K. Singh Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 21 2010 2 6
30. M. Jessup, W.T. Abraham, D.E. Casey, A.M. Feldman, G.S. Francis, and T.G. Ganiats et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 119 2009 1977 2016
31. E.F. Unger, A.M. Thompson, M.J. Blank, and R. Temple Erythropoiesis- stimulating agents-time for a reevaluation N Engl J Med 362 2010 189 192
32. D. Levy, S. Kenchaiah, M.G. Larson, E.J. Benjamin, M.J. Kupka, and K.K. Ho et al. Long-term trends in the incidence of and survival with heart failure N Engl J Med 347 2002 1397 1402
33. C.G. Frazier, K.P. Alexander, L.K. Newby, S. Anderson, E. Iverson, and M. Packer et al. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials J Am Coll Cardiol 49 2007 1450 1458
34. E.M. Hsich, and I.L. Pina Heart failure in women, a need for prospective data J Am Coll Cardiol 54 2009 491 498
35. A. Deswal, and B. Bozkurt Comparison of morbidity in women versus men with heart failure and preserved ejection fraction Am J Cardiol 97 2006 1228 1231